[caption class="snax-figure" align="aligncenter" width="1140"][/caption]
Adrenoleukodystrophy, sometimes called adrenal dysfunction or adrenal hyperplasia, is a serious genetic disorder that causes the accumulation of long, skinny chain fatty acids (VLDFAs) in your brain. When VLDFas stack up over the critical myelin sheaths surrounding nerve fibers, they cause devastating damage to the brain. This may lead to impairments in learning and memory, sensory perception, endocrine system, cardiovascular system, muscular system, and immunity. It is estimated that approximately 1 million Americans suffer from this debilitating condition.
Increasing investment in the field of development of a drug for the rare genetic disorder is uplifting the growth of the adrenoleukodystrophy drugs market. For instance, in May 2020, SwanBio Therapeutics, a developer of biological therapeutics, announced that they have raised US$ 52 million for the advancement of their viral-based gene therapy for adrenomyeloneuropathy. Moreover, the growing focus of key players in the research and development of treatments for adrenoleukodystrophy is further propelling the growth of the adrenoleukodystrophy drug market.
Several genes are involved in the development of adrenoleukodystrophy, including the genes encoding the protein receptor cells that respond to VLDFas. Some people with a form of this disease have a mutation at the receptor gene that inhibits the activity of VLDFas, leaving the receptors unresponsive to insulin and therefore not responding to the growth hormone. The other type of Adrenoleukodystrophy develops when someone has an inherited defect that results in the extra production of the enzyme associated with insulin release.
Read More: https://bit.ly/2T7gHyB
Sign in to leave a comment.